Identifying COPD patients at increased risk of mortality: Predictive value of clinical study baseline data

被引:29
作者
Halpin, David M. G. [1 ]
Peterson, Stefan [2 ]
Larsson, Thomas P. [2 ]
Calverley, Peter M. A. [3 ]
机构
[1] Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England
[2] AstraZeneca, Lund, Sweden
[3] Univ Liverpool, Aintree Chest Ctr, Liverpool L69 3BX, Merseyside, England
关键词
Budesonide/formoterol; Health status; SGRQ; Inhaled corticosteroids; Long-acting beta(2)-agonists; Mortality;
D O I
10.1016/j.rmed.2008.05.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Identifying chronic obstructive pulmonary disease (COPD) patients at increased risk of mortality is an important component of effective disease management. Methods: A pooled analysis of patients with severe COPD, from two well-controlled 1-year studies, was conducted using Cox regression and spline analysis to evaluate predictability of baseline demographic data and in-study variables for mortality risk, and to evaluate the effect of treatment allocation to budesonide and formoterol, versus their respective control groups, on these outcomes. Results: In the pooled analysis, a Cox regression model. reported a higher baseline St George's Respiratory Questionnaire (SGRQ) total score as a significant predictor of mortality (hazard ratio 1.037 [95% confidence interval. 1.021-1.054]; p < 0.0001). The 36-item short-form health survey (SF-36) mental and physical. component scores were also predictive of an increased mortality risk (p < 0.05). Age, forced expiratory volume in 1 s (FEV1), body mass index and smoking status were not significant predictors. Spline analysis of baseline variables revealed a linear association between SGRQ total score and mortality risk over 1 year (logarithmic scale). Other baseline variables, including FEV1, showed different bimodal patterns in the spline analysis. There was no difference in mortality in the formoterol. versus the non-formoterol treatment group while budesonide-containing treatment was associated with reduced 1-year, all-cause, in-study mortality compared with non-budesonide therapy. Conclusion: Health status measured by SGRQ and SF-36 may be important for predicting COPD patients at increased mortality risk, with SGRQ total score emerging as the strongest predictor compared with other baseline covariates. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1615 / 1624
页数:10
相关论文
共 35 条
[1]   Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old [J].
Adams, Kenneth F. ;
Schatzkin, Arthur ;
Harris, Tamara B. ;
Kipnis, Victor ;
Mouw, Traci ;
Ballard-Barbash, Rachel ;
Hollenbeck, Albert ;
Leitzmann, Michael F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (08) :763-778
[2]   Mortality after hospitalization for COPD [J].
Almagro, P ;
Calbo, E ;
de Echagüen, AO ;
Barreiro, B ;
Quintana, S ;
Heredia, JL ;
Garau, J .
CHEST, 2002, 121 (05) :1441-1448
[3]  
[Anonymous], GLOB STRAT DIAGN MAN
[4]   The effects of a smoking cessation intervention on 14.5-year mortality - A randomized clinical trial [J].
Anthonisen, NR ;
Skeans, MA ;
Wise, RA ;
Manfreda, J ;
Kanner, RE ;
Connett, JE .
ANNALS OF INTERNAL MEDICINE, 2005, 142 (04) :233-239
[5]   Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease [J].
Calverley, Peter M. A. ;
Anderson, Julie A. ;
Celli, Bartolome ;
Ferguson, Gary T. ;
Jenkins, Christine ;
Jones, Paul W. ;
Yates, Julie C. ;
Vestbo, Jorgen ;
Calverley, P. M. A. ;
Anderson, J. A. ;
Celli, B. ;
Ferguson, G. T. ;
Jenkins, C. ;
Jones, P. W. ;
Knobil, K. ;
Yates, J. C. ;
Vestbo, J. ;
Cherniack, R. ;
Similowski, T. ;
Cleland, J. ;
Whitehead, A. ;
Wise, R. ;
McGarvey, L. ;
John, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) :775-789
[6]  
Calverley Peter M A, 2006, COPD, V3, P233
[7]   Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease [J].
Calverley, PM ;
Boonsawat, W ;
Cseke, Z ;
Zhong, N ;
Peterson, S ;
Olsson, H .
EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (06) :912-919
[8]   The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease [J].
Celli, BR ;
Cote, CG ;
Marin, JM ;
Casanova, C ;
de Oca, MM ;
Mendez, RA ;
Pinto Plata, V ;
Cabral, HJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (10) :1005-1012
[9]   Readmission rates and life threatening events in COPD survivors treated with non-invasive ventilation for acute hypercapnic respiratory failure [J].
Chu, CM ;
Chan, VL ;
Lin, AWN ;
Wong, IWY ;
Leung, WS ;
Lai, CKW .
THORAX, 2004, 59 (12) :1020-1025
[10]  
Collett D, 2014, MODELLING SURVIVAL D